FormWeb • aliskiren-amLODIPine

Huntsville Hospital

Approved Hospital Formulary

Suggestions or Corrections? Above and Beyond Nominations Formulary Request

Search by class Show Therapeutic Classes

Add Formweb to your mobile device

Android iOS

Medications not yet evaluated by P&T are considered NON-FORMULARY. Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step!
Please be sure to document all clinical activities daily.

Huntsville Hospital

Approved Hospital Formulary

Suggestions or Corrections? Above and Beyond Nominations Formulary Request

Search results for:

aliskiren-amLODIPine

aliskiren-amLODIPine

Non-formulary Calcium Channel Blocker (Dihydropyridine) Formulary
Therapeutic Interchange

Drug Name	Form	Strength	Formulary Unrestricted	Formulary Restricted	Non-Formulary	Interchange
Tekamlo	TABLET, ORAL	150 mg-5 mg, 150 mg-10 mg, 300 mg-5 mg, 300 mg-10 mg

VIEW MORE Dihydropyridines, Renin Inhibitors

Comments:

ORDERED FORMULATION

THERAPEUTIC INTERCHANGE

aliskiren-amLODIPine (Tekamlo)

150 mg-5 mg tablet oral
150 mg-10 mg tablet oral
300 mg-5 mg tablet oral
300 mg-10 mg tablet oral

aliskiren (Tekturna) AND amLODIPine (Norvasc)

ONE 150 mg aliskiren PLUS ONE 5 mg amLODIPine
ONE 150 mg aliskiren PLUS ONE 10 mg amLODIPine
ONE 300 mg aliskiren PLUS ONE 5 mg amLODIPine
ONE 300 mg aliskiren PLUS ONE 10 mg amLODIPine

Reviewed: September 28, 2010

Last updated: Dec. 19, 2017

Black Box Warning: Aliskiren: Pregnancy risk

This site is intended for the staff of Huntsville Hospital.
While others may view accessible pages, Huntsville Hospital makes no warranty, express or implied,
as to the use of this information outside of Huntsville Hospital.
Please note than many documents are accessible via the provided link
only when connected to the Huntsville Hospital intranet.